You picked the Dominican Republic. Our DR page covers institutional REC review on a timeline that varies by study (we confirm it per protocol) and CONABIOS-level review on a timeline that varies by study (we confirm it per protocol). DIGEMAPS is the named regulator. No new DR median is added, and there is no published Miami–DR flight-hour figure. Ask for a study-specific calendar. If you need country 2 — El Salvador, Panama, the Dominican Republic, Chile, Costa Rica, or another jurisdiction we already run — bioaccess® is the same First-in-Human CRO on that next file. First-patient timing varies by study (we confirm it per protocol) and ethics review timed to each committee's meeting schedule are the published LATAM positions. A public hop exists: Dominican Republic, then Australia, then Canada, then an FDA conversation. We describe the pattern. We do not name the sponsor.
| Metric | bioaccess® | Dominican Republic |
|---|---|---|
| Role in your plan | Country 2 / the rescue or expansion path — the same First-in-Human CRO on the next LATAM file | Country 1 — the Dominican Republic you already picked. Our CRO-in-DR page is /clinical-trials-dominican-republic |
| Start-up clock | First-patient timing varies by study (we confirm it per protocol) and ethics review timed to each committee's meeting schedule on the wider LATAM list. Country-2 clocks are asked as a study-specific calendar | Published DR clocks: institutional REC (varies by study; we confirm per protocol); CONABIOS (varies by study; we confirm per protocol). No new DR median is added |
| Regulator | INVIMA, COFEPRIS, ANVISA, ANMAT, ISP, MINSA, DIGEMAPS and the other authorities on our country pages — matched to the second country | DIGEMAPS (Ministry of Public Health) and CONABIOS — on our DR pages. Those are the regulators |
| Per-patient / program cost | Budget depends on study design; we provide a study-specific quote. | Covered on our DR page; no new figure here |
| Entity | None to stand up for the trial file. Contract and start | bioaccess® does not claim a Dominican clinical-trial legal entity. Our market-access page states a Dominican entity for the Authorized Representative / registration-holder role — that is a second file |
| FDA acceptance & data applicability | Data conducted under GCP (ISO 14155 for devices; ICH E6 for drugs) is eligible for FDA submission and review under 21 CFR 812.28 or 312.120. Eligibility is not clearance or approval | Our DR page states the same 21 CFR 812.28 eligibility for Dominican Republic data when GCP, ethics, and consent are met |
| Distance & time zone from the U.S. | Same or adjacent U.S. time zones; ~3–8 hour flights on the published LATAM compare (Australia page) | Our DR page covers direct US flights and US East Coast time-zone alignment. There is no published Miami–DR flight-hour figure |
| Where the hub is the better page | Country 2 — El Salvador, Panama, the Dominican Republic, Chile, Costa Rica, or another jurisdiction we already run | CRO in the Dominican Republic / CRO en República Dominicana — that category lives on /clinical-trials-dominican-republic |
Comparison uses widely-known category facts about Dominican Republic and published US benchmark ranges — not Dominican Republic-specific figures. bioaccess® figures reflect our FIH-12™ operating model.
You picked the Dominican Republic. Our CRO-in-DR page covers that category: Miami headquarters, DIGEMAPS, CONABIOS, REC (varies by study; we confirm per protocol), CONABIOS (varies by study; we confirm per protocol). If you only need the Dominican Republic file, start there.
This comparison covers country 2. Another Latin American jurisdiction after a DR first-in-human, or a hop out of region. bioaccess® is the same First-in-Human CRO on that next file. bioaccess® does not claim a Dominican clinical-trial legal entity. There is no published Miami–DR flight-hour figure. Direct US flights and US East Coast time-zone alignment are on our DR page.
A public hop exists: Dominican Republic, then Australia, then Canada, then an FDA conversation. We describe the pattern. We do not name the sponsor, the device, or commercial terms. bioaccess® is built for the Latin American legs of a hop like that.
Foreign device data is eligible for FDA submission and review under 21 CFR 812.28 when GCP / ISO 14155, ethics, and consent are met. Eligibility is not clearance or approval. Ask for a study-specific calendar. No new DR median is added.
No. Our CRO-in-DR page, /clinical-trials-dominican-republic, covers CRO in the Dominican Republic / CRO en República Dominicana, DIGEMAPS, CONABIOS, and the REC and CONABIOS review steps (timing varies by study; we confirm per protocol). This comparison covers country 2 after a DR first-in-human.
Our DR page covers institutional REC review on a timeline that varies by study (we confirm it per protocol) and CONABIOS-level review on a timeline that varies by study (we confirm it per protocol). No new median is added. Ask for a study-specific calendar.
There is no published Miami–DR flight-hour figure. Our DR page covers direct US flights and US East Coast time-zone alignment.
A public multi-country hop exists: a first-in-human start in the Dominican Republic, then Australia, then Canada, then an FDA conversation. We describe the pattern. We do not name the sponsor, the device, or commercial terms. bioaccess® is built for the Latin American legs of a hop like that.
You only need the CRO-in-Dominican-Republic category — DIGEMAPS, CONABIOS, sites named on that page, and the published clocks. Go to /clinical-trials-dominican-republic. Use this comparison when country 1 is the Dominican Republic and you need country 2.
All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call